DEA reclassifies plant-derived marijuana medicine November 26, 2018 AggregatedNews Policy & Legal 0 Comments According to a release issued by the National Organization for the Reform of Marijuana Laws, Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified by the U.S. Drug Enforcement Administration to Schedule V — the lowest restriction… Read More→